Emerging Healthcare Solutions, Inc. (PinkSheets: EHSI) announced today that it locked down an option for a profit participation deal with biotech firm Celulas Genetica. Celulas Genetica works to develop new major medical solutions using adult stem cell research. This industry promises to be a major driver of growth in the medical and pharmaceutical industries over the next ten years. Celulas Genetica hopes to play a leading role in the development of new medical breakthroughs.
Billions of dollars have gone into adult stem cell research and breakthrough cures appear to be on the way. Celulas Genetica aims to provide stem cell research support to researchers and universities in Central and South America where there are fewer restrictions on such research than there are in the United States. Stem cell cures could produce billions of dollars of revenue for the companies that develop these cures and bring them to market.
The option agreement gives the companies a mutual due diligence review period prior to completing an investment and profit sharing agreement that could earn EHSI up to 20% of the Company’s long-term profits.
Stem cell research stocks in the Biotechnology sector that give context to the importance this exploding industry include ViaCell (NASDAQ: VIAC), a Cambridge Massachusetts company backed by biotech giant Amgen (NASDAQ: AMGN) and Genzyme (NASDAQ: GENZ). The Biotechnology sector also includes Biogen Idec (NASDAQ: BIIB).
Source: Emerging Healthcare Solutions, Inc.